Cargando…

Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan

IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been found to improve low-grade systemic and tissue inflammation; however, the association between SGLT2 inhibitor use and the incidence of dry eye disease (DED) has not been explored. OBJECTIVE: To investigate the association betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yu-Chen, Hung, Jia-Horung, Chang, Kai-Cheng, Sun, Chi-Chin, Huang, Yi-Hsun, Lee, Chaw-Ning, Hung, Ming-Jui, Lai, Chi-Chun, Shao, Shih-Chieh, Lai, Edward Chia-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500553/ https://www.ncbi.nlm.nih.gov/pubmed/36136333 http://dx.doi.org/10.1001/jamanetworkopen.2022.32584

Ejemplares similares

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes
por: Eriksson, Olof, et al.
Publicado: (2022)

Comparative anatomical outcomes of high-flow vs. low-flow phacoemulsification cataract surgery: A systematic review and meta-analysis
por: Kuo, Po-Chin, et al.
Publicado: (2022)

Long-Term Outcome of Treatment with 2% Topical Ganciclovir Solution in Cytomegalovirus Anterior Uveitis and Corneal Endotheliitis
por: Chen, Po-Jui, et al.
Publicado: (2022)

Optogenetic Analysis of Depolarization-Dependent Glucagonlike Peptide-1 Release
por: Chimerel, Catalin, et al.
Publicado: (2017)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus
por: Yao, Yen-Po, et al.
Publicado: (2023)

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties
por: Li, Hung‐Yuan
Publicado: (2020)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW
por: Boss, Marti, et al.
Publicado: (2020)

Strategies to maintain persistence of opioid agonist therapy during the novel coronavirus pandemic in Taiwan
por: Shih, Cheng-Chan, et al.
Publicado: (2020)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
por: Zhou, Jiandong, et al.
Publicado: (2022)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022)

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021)

Associations of thiazide use with skin cancers: a systematic review and meta-analysis
por: Shao, Shih-Chieh, et al.
Publicado: (2022)

Orbital complications of paranasal sinusitis in Taiwan, 1988 through 2015: Acute ophthalmological manifestations, diagnosis, and management
por: Chang, Yi-Sheng, et al.
Publicado: (2017)

Angiotensin converting enzyme and sodium glucose cotransporter inhibitors alleviate inflammatory effects of SARS-CoV-2 in cardiomyocytes
por: Wong, Chun-Ka, et al.
Publicado: (2022)

Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
por: Tsai, Ming-Lung, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
por: Ko, Hwa Yeon, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)

Major ocular trauma in Taiwan: 2002–2004 versus 2012–2014
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan
por: Chung, Mu-Chi, et al.
Publicado: (2021)

Scleritis and anterior uveitis may herald the development of an epibulbar tumor in patients with extranodal Rosai-Dorfman disease: a case report
por: Lee, Yu-Kuei, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
por: Li, Hang-Long, et al.
Publicado: (2022)

Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis
por: Lui, David Tak Wai, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Author Correction: Major ocular trauma in Taiwan: 2002–2004 versus 2012–2014
por: Chang, Yi-Sheng, et al.
Publicado: (2018)

CORRIGENDUM FOR “Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM”
Publicado: (2020)

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitor plus pioglitazone vs pioglitazone alone in patients with diabetes mellitus: A systematic review and meta‐analysis of randomized controlled trials
por: Liao, Hung‐Wei, et al.
Publicado: (2018)

Oral glutamine supplements reduce concurrent chemoradiotherapy-induced esophagitis in patients with advanced non-small cell lung cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2019)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dat5pn0i78mo4ie0868unueuou